Boston Scientific has obtained CE mark approval for its Synergy Everolimus-Eluting platinum chromium coronary stent system, designed to improve post-implant vessel healing. The coronary stent, which features a combination of ...
Boston Scientific has completed enrolling first patient in a EVOLVE II clinical trial of its Synergy Everolimus-Eluting platinum chromium coronary stent system. The CE-marked stent features a combination of everolimus drug and ...
Tags: Synergy Everolimus Eluting platinum chromium coronary stent system